Revolution Medicines, Inc. Share Price
RVMDRevolution Medicines, Inc. Stock Performance
Open $79.83 | Prev. Close $78.50 | Circuit Range N/A |
Day Range $77.94 - $79.83 | Year Range $29.17 - $81.93 | Volume 45,664 |
Average Traded $78.67 |
Revolution Medicines, Inc. Share Price Chart
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
02-Jan-26 | $79.83 | $79.02 | -0.81% |
31-Dec-25 | $79.66 | $79.66 | +0.00% |
30-Dec-25 | $80.32 | $79.66 | -1.09% |
29-Dec-25 | $80.02 | $80.53 | -0.23% |
26-Dec-25 | $80.57 | $80.72 | -0.51% |
24-Dec-25 | $80.78 | $81.14 | +1.14% |
23-Dec-25 | $80.54 | $80.22 | -0.47% |
FAQs on Revolution Medicines, Inc. Share Price
Can I buy Revolution Medicines, Inc. shares in India?
What is the share price of Revolution Medicines, Inc.?
What is the 5 year returns of Revolution Medicines, Inc.?
What are the high & low stock price of Revolution Medicines, Inc. today?
What is the 52-week high and low of Revolution Medicines, Inc. stock?